Brett Kavaja
About Brett Kavaja
Brett Kavaja is the Director of Global Marketing, Early Commercialization at Bristol Myers Squibb, with over 20 years of experience in the pharmaceutical and biotechnology industries, specializing in oncology.
Company
Brett Kavaja is currently employed at Bristol Myers Squibb in Summit, New Jersey. He serves as the Director of Global Marketing, Early Commercialization for the company. Bristol Myers Squibb is a globally recognized biopharmaceutical company known for its work in advancing innovative medicines for various health conditions.
Title
Brett Kavaja holds the title of Director, Global Marketing, Early Commercialization at Bristol Myers Squibb. In this role, he focuses on the early stages of marketing strategies for new pharmaceutical products, particularly in the biopharma sector.
Education and Expertise
Brett Kavaja earned his MBA in Marketing from Fairleigh Dickinson University, completing his studies in 2003. He also holds a Bachelor's degree in Chemistry from West Virginia University, obtained in 1996. With over 20 years of experience in the pharmaceutical and biotechnology industries, his specific expertise lies in oncology commercial development, marketing intelligence, and forecasting.
Professional Background
Brett Kavaja has accumulated extensive experience across several notable companies in the pharmaceutical sector. At Eisai US, he was the Director of Global Oncology Commercial Development from 2014 to 2017 and the Associate Director of Oncology Global Marketing / Demand Innovation from 2011 to 2014. His early career included roles at Daiichi Sankyo, Inc, Abraxis Bioscience, NovoNordisk, and Bayer, where he gained significant experience in portfolio management, marketing analytics, and product evaluations.
Oncology Marketing and Commercial Development
Throughout his career, Brett Kavaja has specialized in oncology, holding various roles focused on commercial development and marketing within this therapeutic area. His work has included responsibilities in global marketing strategies, demand innovation, and portfolio management, particularly in the oncology sector. His positions at Eisai US and other companies have contributed to his deep expertise in bringing oncology products to market.